Policy Forum 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
暂无分享,去创建一个
M. Albert | L. Schneider | P. Snyder | R. Petersen | M. Carrillo | R. Sperling | M. Sano | D. Knopman | W. Thies | D. Drachman | S. DeKosky | P. Aisen | P. Maruff | K. Herrup | R. Au | W. Mobley | K. Fargo | M. Corrada | B. Lamb | L. Bain | R. Nixon | A. Khachaturian | S. Paul | R. Logsdon | M. Haas | E. KlunkWilliam | David Morgan | Milestone Workgroup | D. Knopman
[1] Jens C. Pruessner,et al. Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation , 2015, Alzheimer's & Dementia.
[2] J. Cummings,et al. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.
[3] H. Soininen,et al. A MULTIDOMAIN, TWO-YEAR, RANDOMIZED CONTROLLED TRIAL TO PREVENT COGNITIVE IMPAIRMENT: THE FINGER STUDY , 2014, Alzheimer's & Dementia.
[4] Maria C. Carrillo,et al. International Alzheimer's Disease Research Portfolio (IADRP) aims to capture global Alzheimer's disease research funding , 2014, Alzheimer's & Dementia.
[5] D. Bennett,et al. Alzheimer's disease in African Americans: risk factors and challenges for the future. , 2014, Health affairs.
[6] R. Egge. The Alzheimer's Study Group's recommendations five years later: planning has advanced, but agenda remains unfinished. , 2014, Health affairs.
[7] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[8] W. Klunk,et al. Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture , 2013, Neuron.
[9] Angela Cacace,et al. Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease , 2013, Alzheimer's & Dementia.
[10] R. Schilsky,et al. Reevaluating the Accelerated Approval Process for Oncology Drugs , 2013, Clinical Cancer Research.
[11] R. Katz,et al. Regulatory innovation and drug development for early-stage Alzheimer's disease. , 2013, The New England journal of medicine.
[12] K. Blennow,et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.
[13] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[14] Paul Edison,et al. Drug repositioning for Alzheimer's disease , 2012, Nature Reviews Drug Discovery.
[15] R. Petersen,et al. The epidemiology of Alzheimer’s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials , 2012, Alzheimer's & Dementia.
[16] L. Fratiglioni,et al. Dementia prevention: current epidemiological evidence and future perspective , 2012, Alzheimer's Research & Therapy.
[17] J. Karlawish,et al. Countrywide strategic plans on Alzheimer’s disease: Developing the framework for the international battle against Alzheimer’s disease , 2011, Alzheimer's & Dementia.
[18] Irving E. Vega,et al. Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[19] Ruili Huang,et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.
[20] J. Woodcock,et al. Development of novel combination therapies. , 2011, The New England journal of medicine.
[21] J. Karlawish,et al. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials , 2010, Alzheimer's Research & Therapy.
[22] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[23] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[24] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[25] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[26] K. Langa,et al. Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites , 2009, Alzheimer's & Dementia.
[27] T. Meuser,et al. Predictors of Physician Referral for Patient Recruitment to Alzheimer Disease Clinical Trials , 2009, Alzheimer disease and associated disorders.
[28] K. Langa,et al. Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study , 2007, Neuroepidemiology.
[29] J. Trojanowski,et al. Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery , 2006, Alzheimer's & Dementia.
[30] J. Demirovic,et al. Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. , 2003, Annals of epidemiology.
[31] D. Bennett,et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. , 2003, Archives of neurology.
[32] R. Costa,et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan , 2001, Neurology.
[33] Habib Zaidi,et al. Amyloid-β positron emission tomography imaging probes: a critical review. , 2013, Journal of Alzheimer's disease : JAD.
[34] Keith A. Johnson,et al. ORAL SESSIONS: IC-O3 EMERGING TECHNIQUES IC-O3-01 THE CENTILOID SCALE: STANDARDIZATION OF AMYLOID IMAGING MEASURES , 2013 .